Drug Discovery for Parkinson's With Mutations in the GBA Gene

Part of paid clinical trials in New York, New York.

Sponsor
New York Stem Cell Foundation Research Institute
Study ID
NCT05536388
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Biological Sample Collection — OTHER
    Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure)

Study Details

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate Parkinson's disease research and drug development by using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and/or store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for Parkinson's disease.

Key Dates

Start date
Jul 15, 2022
Status verified
Jul 2024
Primary completion
Jul 15, 2025
Completion
Jul 15, 2025

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: Parkinson's Disease
    Subjects in this group will have a diagnosis of Parkinson's disease with or without a known GBA gene mutation.
  • Arm: Gaucher Disease
    Subjects in this group with have a diagnosis of Gaucher disease with or without a known GBA gene mutation.
  • Arm: Healthy Control
    Subjects in this group will serve as healthy controls.

Primary Outcome Measure

Establishment of a diverse bank of biological samples, stem cell lines, derivatives, and associated information. [ Time Frame: Baseline ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The New York Stem Cell Foundation Research InstituteNew YorkNew York10019
Clinical Research Office
212-927-1801
Laura Andres-Martin (PRINCIPAL_INVESTIGATOR)

Find similar trials in New York, NY

Related Studies